Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson’s disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging

@inproceedings{Weng2017QuantitativeAO,
  title={Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson’s disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging},
  author={Chi-Chang Weng and Zi-An Chen and Ko-Ting Chao and T Ee and Kun-Ju Lin and M H Chan and Ing-Tsung Hsiao and Tzu-Chen Yen and M P Kung and Ching-Han Hsu and Shiaw-Pyng Wey},
  booktitle={PloS one},
  year={2017}
}
18F-9-Fluoropropyl-(+)-dihydrotetrabenazine [18F-FP-(+)-DTBZ] positron emission tomography (PET) has been shown to detect dopaminergic neuron loss associated with Parkinson's disease (PD) in human and neurotoxin-induced animal models. A polyphenol compound, magnolol, was recently proposed as having a potentially restorative effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- or 6-hydroxydopamine-treated animal models. In this study, 18F-FP-(+)-DTBZ PET was used to determine the… CONTINUE READING